Association of high baseline ferritin with tocilizumab administration for CRS in relapsed/refractory multiple myeloma patients treated with bb2121 anti-BCMA CAR T cells.

Jesus G. Berdeja,Yi Lin,James N. Kochenderfer,Noopur Raje,Nikhil C. Munshi,David Siegel,Michaela Liedtke,Deepu Madduri,Jacalyn Rosenblatt,Marcela V. Maus,Ashley Turka,Lyh Ping Lam,Kristen Hege,Timothy Brandon Campbell,Monica Massaro,Fabio Petrocca,Sundar Jagannath

Association of high baseline ferritin with tocilizumab administration for CRS in relapsed/refractory multiple myeloma patients treated with bb2121 anti-BCMA CAR T cells.

2018

Jesus G. Berdeja
Yi Lin
James N. Kochenderfer
Noopur Raje
Nikhil C. Munshi
David Siegel
Michaela Liedtke
Deepu Madduri
Jacalyn Rosenblatt
Marcela V. Maus
Ashley Turka
Lyh Ping Lam
Kristen Hege
Timothy Brandon Campbell
Monica Massaro
Fabio Petrocca
Sundar Jagannath

e15062Background: Cytokine release syndrome (CRS) is the most common risk associated with chimeric antigen receptor (CAR) T cell therapies. Identification of predictors of severe CRS may enable ear...

Keywords:

Tocilizumab
Refractory Multiple Myeloma
Oncology
Anti-BCMA CAR T Cells
Pathology
Ferritin
Internal medicine
Medicine
Immunology
Chimeric antigen receptor
Multiple myeloma
T cell
Cytokine release syndrome
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations